Related Experiment Video
Updated: Jun 17, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations
Rabab Debs1, Christel Depienne, Agnès Rastetter
1Federation of Nervous System Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital de la Salpêtrière, Université Pierre et Marie Curie, Paris CEDEX 13, France.
Objective:
To report the first 2 European cases of biotin-responsive basal ganglia disease and novel SLC19A3 mutations.
Design:
Case reports.
Setting:
University hospital. Patients A 33-year-old man and his 29-year-old sister, both of Portuguese ancestry, presented with recurrent episodes of encephalopathy. Between episodes patients exhibited generalized dystonia, epilepsy, and bilateral hyperintensities of the caudate and putamen.
Main Outcome Measures:
Clinical and radiologic findings.
Results:
Administration of high doses of biotin or of a combination of biotin and thiamine during encephalopathies resulted in spectacular clinical and radiologic improvement in both patients. Sequencing of the SLC19A3 disclosed 2 novel mutations, both of which created premature stop codons in the protein sequence of hTHTR2.
Conclusion:
This study demonstrates that biotin-responsive basal ganglia disease is a panethnic condition. A therapeutic trial with high doses of biotin and thiamine seems mandatory in every unexplained encephalopathy with bilateral lesions of putamen and caudate nuclei.
Related Concept Videos
Pedigree Analysis
Lysosomal Hydrolases
Huntington Disease l: Introduction
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Parkinson Disease ll: Pathophysiology
Parkinson Disease l: Introduction
